- Home
- CORT
as 06-20-2025 4:00pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 8.1B | IPO Year: | N/A |
| Target Price: | $142.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.14 | EPS Growth: | 8.36 |
| 52 Week Low/High: | $28.10 - $117.33 | Next Earning Date: | 07-28-2025 |
| Revenue: | $685,446,000 | Revenue Growth: | 30.93% |
| Revenue Growth (this year): | 35.85% | Revenue Growth (next year): | 35.22% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Robb Gary Charles | CORT | Chief Business Officer | Jun 16 '25 | Sell | $70.77 | 3,185 | $225,402.45 | 13,364 | |
| Swisher Daniel N JR | CORT | Director | Jun 10 '25 | Sell | $70.61 | 2,200 | $155,342.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Jun 10 '25 | Sell | $72.56 | 20,000 | $1,448,474.57 | 5,487 | |
| Lyon Joseph Douglas | CORT | See Remarks | Jun 2 '25 | Sell | $78.31 | 5,000 | $390,218.44 | 9,009 | |
| Maduck Sean | CORT | See Remarks | Jun 2 '25 | Sell | $79.36 | 20,000 | $1,581,686.49 | 17,705 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Jun 2 '25 | Sell | $81.86 | 40,000 | $3,314,309.74 | 2,923,352 | |
| Robb Gary Charles | CORT | Chief Business Officer | May 20 '25 | Sell | $75.85 | 2,279 | $172,862.15 | 13,364 | |
| MAHONEY DAVID L | CORT | Director | May 16 '25 | Sell | $74.41 | 27,352 | $2,030,452.49 | 0 | |
| Guyer William | CORT | Chief Development Officer | May 16 '25 | Sell | $74.17 | 32,262 | $2,393,014.49 | 5,487 | |
| Swisher Daniel N JR | CORT | Director | May 12 '25 | Sell | $71.86 | 2,200 | $158,526.00 | 0 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Argus Research
11 days ago
CORT: Raising target price to $79.00
Benzinga
16 days ago
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
MT Newswires
16 days ago
Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal
Business Wire
16 days ago
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
MT Newswires
16 days ago
Corcept Therapeutics Insider Sold Shares Worth $1,581,687, According to a Recent SEC Filing
MT Newswires
16 days ago
Corcept Therapeutics Insider Sold Shares Worth $3,314,310, According to a Recent SEC Filing
StockStory
17 days ago
2 Profitable Stocks to Target This Week and 1 to Avoid
Zacks
17 days ago
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.